Rubicon Research (RUBICON) Q4 24/25 earnings summary

Executive summary

• Consolidated financial statements present a true and fair view in accordance with Ind AS as of 31 March 2025, with an unmodified audit opinion from Deloitte Haskins & Sells LLP.

• The group operates primarily in the pharmaceutical sector, with a global presence through multiple subsidiaries in the US, Canada, Australia, Singapore, Estonia, and India.

• Major business activities include research, development, manufacturing, and commercialization of pharmaceutical products, including branded and generic medicines.

Financial highlights

• Revenue from operations increased to ₹128,427.21 lakhs for FY25 from ₹85,388.91 lakhs in FY24, a 50% year-over-year growth.

• Net profit attributable to owners rose to ₹13,436.27 lakhs from ₹9,101.22 lakhs year-over-year.

• EBITDA and EBIT improved, with profit before tax at ₹19,452.44 lakhs, up from ₹10,285.72 lakhs.

• Basic EPS increased to ₹8.82 from ₹5.98; diluted EPS to ₹8.68 from ₹5.91.

• Cash and cash equivalents at year-end were ₹10,497.77 lakhs, up from ₹5,060.49 lakhs.

Outlook and guidance

• The Board has proposed a final dividend of ₹0.02 per equity share, subject to shareholder approval.

• Management expects continued growth, leveraging recent acquisitions and expanded capabilities in branded pharmaceuticals in the US.